Acta Crystallogr C Struct Chem
September 2020
A series of related acetylacetonate-carbonyl-rhodium compounds substituted by functionalized phosphines has been prepared in good to excellent yields by the reaction of [Rh(acac)(CO)] (acac is acetylacetonate) with the corresponding allyl-, cyanomethyl- or cyanoethyl-substituted phosphines. All compounds were fully characterized by P, H, C NMR and IR spectroscopy. The X-ray structures of (acetylacetonato-κO,O')(tert-butylphosphanedicarbonitrile-κP)carbonylrhodium(I), [Rh(CHO)(CO)(CHN)] or [Rh(acac)(CO)(BuP(CHCN)}] (2b), (acetylacetonato-κO,O')carbonyl[3-(diphenylphosphanyl)propanenitrile-κP]rhodium(I), [Rh(CHO)(CHN)(CO)] or [Rh(acac)(CO){PhP(CHCHCN)}] (2h), and (acetylacetonato-κO,O')carbonyl[3-(di-tert-butylphosphanyl)propanenitrile-κP]rhodium(I), [Rh(CHO)(CHN)(CO)] or [Rh(acac)(CO){BuP(CHCHCN)}] (2i), showed a square-planar geometry around the Rh atom with a significant trans influence over the acetylacetonate moiety, evidenced by long Rh-O bond lengths as expected for poor π-acceptor phosphines.
View Article and Find Full Text PDFSummary: Vertigo has a negative impact on quality of life; therefore, it is important to find an effective and convenient therapy that allows patients to continue their everyday tasks as soon as possible and to have a better quality of life.
Methods: There were two formulations used to assess the effectiveness in vertigo treatment from peripheral origin: nimodipine administrated three times daily (Nimotop®) 30 mg versus nimodipine AP administrated once daily (Tropocer®) 90 mg; both of them in a administrated in a prospective, randomized, double-blind, double dummy, multicenter and parallel-group study, where patients with peripheral vertigo defined as a score ≥7 on the Vertigo-Dizziness Differential Diagnosis Score were included. The patients were evaluated by vertigo severity index and vestibular disability index.